Discovery of Potent, Selective Chymase Inhibitors via Fragment Linking Strategies

被引:27
|
作者
Taylor, Steven J. [1 ]
Padyana, Anil K. [1 ]
Abeywardane, Asitha [1 ]
Liang, Shuang [1 ]
Hao, Ming-Hong [6 ]
De Lombaert, Stephane [7 ]
Proudfoot, John [1 ]
Farmer, Bennett S., III [3 ]
Li, Xiang [1 ]
Collins, Brandon [1 ]
Martin, Leslie [4 ]
Albaugh, Daniel R. [1 ]
Hill-Drzewi, Melissa [5 ]
Pullen, Steven S. [2 ]
Takahashi, Hidenori [1 ]
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Dept Med Chem, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Pharmaceut Inc, Cardiometab Dis, Ridgefield, CT 06877 USA
[3] Boehringer Ingelheim Pharmaceut Inc, IS Sci Informat Management, Ridgefield, CT 06877 USA
[4] Boehringer Ingelheim Pharmaceut Inc, IS Res Data Acquisit, Ridgefield, CT 06877 USA
[5] Bristol Myers Squibb Co, Lead Evaluat Dept, Wallingford, CT 06492 USA
[6] H3 Biomed, Cambridge, MA 02139 USA
[7] Karos Pharmaceut, New Haven, CT 06511 USA
关键词
MAST-CELLS; PATHOPHYSIOLOGICAL ROLE; MECHANISMS; INFARCTION; FIBROSIS; TARGET;
D O I
10.1021/jm400138z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chymase plays an important and diverse role in the homeostasis of a number of cardiovascular processes. Herein, we describe the identification of potent, selective chymase inhibitors, developed using fragment-based, structure-guided linking and optimization techniques. High-concentration biophysical screening methods followed by high-throughput crystallography identified an oxindole fragment bound to the S1 pocket of the protein exhibiting a novel interaction pattern hitherto not observed in chymase inhibitors. X-ray crystallographic structures were used to guide the elaboration/linking of the fragment, ultimately leading to a potent inhibitor that was >100-fold selective over cathepsin G and that mitigated a number of liabilities associated with poor physicochemical properties of the series it was derived from.
引用
收藏
页码:4465 / 4481
页数:17
相关论文
共 50 条
  • [1] Development of potent inhibitors by fragment-linking strategies
    Bedwell, Elizabeth, V
    McCarthy, William J.
    Coyne, Anthony G.
    Abell, Chris
    CHEMICAL BIOLOGY & DRUG DESIGN, 2022, 100 (04) : 469 - 486
  • [2] Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach
    Mobitz, Henrik
    Machauer, Rainer
    Holzer, Philipp
    Vaupel, Andrea
    Stauffer, Frederic
    Ragot, Christian
    Carayatti, Giorgio
    Scheufler, Clemens
    Fernandez, Cesar
    Hommel, Ulrich
    Tiedt, Ralph
    Beyer, Kim S.
    Chen, Chao
    Zhu, Hugh
    Gaul, Christoph
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (03): : 338 - 343
  • [3] Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase
    Greco, Michael N.
    Hawkins, Michael J.
    Powell, Eugene T.
    Almond, Harold R., Jr.
    de Garavilla, Lawrence
    Hall, Jeffrey
    Minor, Lisa K.
    Wang, Yuanping
    Corcoran, Thomas W.
    Di Cera, Enrico
    Cantwell, Angelene M.
    Savvides, Savvas N.
    Damiano, Bruce P.
    Maryanoff, Bruce E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (08) : 1727 - 1730
  • [4] Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit
    Qiu, Hui
    Liu-Bujalski, Lesley
    Caldwell, Richard D.
    Follis, Ariele Viacava
    Gardberg, Anna
    Goutopoulos, Andreas
    Grenningloh, Roland
    Head, Jared
    Johnson, Theresa
    Jones, Reinaldo
    Mochalkin, Igor
    Morandi, Federica
    Neagh, Constantin
    Sherer, Brian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (17) : 2939 - 2944
  • [5] Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping
    Ji, Haitao
    Li, Huiying
    Martasek, Pavel
    Roman, Linda J.
    Poulos, Thomas L.
    Silverman, Richard B.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (03) : 779 - 797
  • [6] Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors
    Murray, Christopher W.
    Berdini, Valerio
    Buck, Ildiko M.
    Carr, Maria E.
    Cleasby, Anne
    Coyle, Joseph E.
    Curry, Jayne E.
    Day, James E. H.
    Day, Phillip J.
    Hearn, Keisha
    Iqbal, Aman
    Lee, Lydia Y. W.
    Martins, Vanessa
    Mortenson, Paul N.
    Munck, Joanne M.
    Page, Lee W.
    Patel, Sahil
    Roomans, Susan
    Smith, Kirsten
    Tamanini, Emiliano
    Saxty, Gordon
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (07): : 798 - 803
  • [7] Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors
    Howard, N
    Abell, C
    Blakemore, W
    Chessari, G
    Congreve, M
    Howard, S
    Jhoti, H
    Murray, CW
    Seavers, LCA
    van Montfort, RLM
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (04) : 1346 - 1355
  • [8] Fragment-based drug discovery of potent and selective CYP121 inhibitors for tuberculosis
    Kavanagh, Madeline
    Coyne, Anthony
    James, Guy
    McLean, Kirsty
    Hudson, Sean
    de Carvalho, Luis Pedro
    Munro, Andrew
    Abell, Christopher
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [9] Fragment-based drug discovery of potent and selective MKK3/6 inhibitors
    Bigi, Simone
    Adams, Mark
    Kobayashi, Toshitake
    Lawson, David
    Saitoh, Morihisa
    Shimagawa, Kenichiro
    Hixon, Mark
    Smith, Chris
    Tatamiya, Takayuki
    Goto, Masayuki
    Russo, Joseph
    Grimshaw, Ched
    Swann, Steve
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [10] Fragment-based drug discovery of potent and selective MKK3/6 inhibitors
    Adams, Mark
    Kobayashi, Toshitake
    Lawson, J. David
    Saitoh, Morihisa
    Shimokawa, Kenichiro
    Bigi, Simone V.
    Hixon, Mark S.
    Smith, Christopher R.
    Tatamiya, Takayuki
    Goto, Masayuki
    Russo, Joseph
    Grimshaw, Charles E.
    Swann, Steven
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (03) : 1086 - 1089